Sat Dec 27 16:50:00 UTC 2025: Summary:
As flu season intensifies, this article highlights alternative treatment options to the commonly prescribed Tamiflu. Xofluza, a single-dose pill, is presented as a strong alternative, potentially offering fewer side effects and faster viral shedding. However, the article also points out the increasing concern about the influenza virus developing resistance to Xofluza. The CDC recommends four antiviral drugs: Tamiflu, Xofluza, Relenza, and Rapivab, each with specific age approvals, administration methods, and potential side effects. Tamiflu remains a favored treatment due to concerns about Xofluza resistance, especially in children. The article also covers Rapivab and Relenza, noting their specific administrations, side effects, and limitations. Experts emphasize the need for continued research on combination antiviral treatments for severe cases of the flu.
News Article:
Beyond Tamiflu: Alternative Flu Treatments Emerge Amid Rising Cases
[City, State] – As flu season intensifies across the United States, health officials are reminding the public that Tamiflu isn’t the only option for combating the illness. While Tamiflu remains a common prescription, alternative treatments like Xofluza offer potential benefits, including a single-dose regimen and potentially fewer side effects, experts say.
According to the Centers for Disease Control and Prevention (CDC), four antiviral drugs are recommended for treating the flu: Tamiflu (oseltamivir), Xofluza (baloxavir), Relenza (zanamivir), and Rapivab (peramivir). Each medication has its own set of guidelines for use, including age approvals, administration methods, and potential side effects.
Xofluza, approved for individuals aged 5 and older, is administered as a single-dose tablet. “One dose. Fewer side effects. More insurances are covering the cost of it now and manufacturer coupon makes it less expensive than in previous years,” said Dr. Ari Brown, a pediatrician based in Texas and author of the Baby 411 book series, adding that she prefers it for her patients. “But all of the factors above–cost, ability to swallow a pill, availability can impact that decision.”
Despite its advantages, growing concerns exist about the influenza virus developing resistance to Xofluza, particularly in younger children. This resistance can lead to a longer duration of symptoms.
“This emergence of baloxavir resistance is associated with a longer duration of symptoms,” said Dr. Tim Uyeki, chief medical officer of the influenza division at the CDC’s National Center for Immunization and Respiratory Diseases
Tamiflu, taken twice daily for five days, remains a preferred choice for hospitalized patients and individuals with progressive illness. Other options include Rapivab, administered intravenously, and Relenza, an inhaled powder not recommended for those with breathing problems like asthma.
Health officials emphasize that antiviral medications work best when started within 48 hours of symptom onset. The CDC recommends consulting with a healthcare provider to determine the most appropriate treatment option based on individual health status and risk factors. Experts also advocate for further research into combination antiviral treatments for severe flu cases.
First Piper 